1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIALAviv Pudipeddi, Rupert W. Leong, Yoon‐Kyo An et al.|Gastroenterology|2023Cited by 2
Su1899: EXTENSIVE DISEASE CLEARANCE AS A NOVEL COMPOSITE ENDPOINT TO PREDICT LONG-TERM RELAPSE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIALAviv Pudipeddi, Rupert W. Leong, Sudarshan Paramsothy et al.|Gastroenterology|2025Cited by 0
Su1943: CORRELATION OF BIOCHEMICAL, ENDOSCOPIC AND HISTOLOGIC ENDPOINTS IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIALAviv Pudipeddi, Rupert W. Leong, Sudarshan Paramsothy et al.|Gastroenterology|2025Cited by 0